ELITE PHARMACEUTICAL
ELI
ELI was delisted on the 20th of May, 2009.
4 hedge funds and large institutions have $130K invested in ELITE PHARMACEUTICAL in 2016 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 4 → 4 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
17% less capital invested
Capital invested by funds: $156K → $130K (-$25.9K)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WRM
Westport Resources Management
Westport,
Connecticut
|
-$1K |
ELI Hedge Fund Activity: Q1 2016 in Review
4 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in ELITE PHARMACEUTICAL (ELI) for Q1 2016, worth a combined $130K — down 17% from $156K a quarter earlier.
Fund positioning in ELI was balanced in Q1 2016: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.
The largest seller was Westport Resources Management, exiting entirely with an estimated $1K sold.
- 4 institutional investors held ELITE PHARMACEUTICAL (ELI) as of Q1 2016, unchanged from Q4 2015.
- Funds reported $130K of ELITE PHARMACEUTICAL stock for Q1 2016, down 17% quarter-over-quarter.
- 1 fund opened new ELITE PHARMACEUTICAL positions in Q1 2016 and 1 closed out, a net change of 0 holders.
- The largest ELITE PHARMACEUTICAL seller in Q1 2016 was Westport Resources Management, an estimated $1K sold.
Based on aggregated 13F filings for Q1 2016.